HSPC immunophenotype was similar for pre-TP53-sAML and CP TP53-MPN patients (Extended Data Fig. 9a–c), and clearly distinct from the TP53-sAML stage (Extended Data Fig. 9d). This evidence concerns the gene CP and myeloproliferative disorder.